Urethane

Summary

Urethane (CHEMBL462547) is an approved small molecule.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Clinical trials: 1
• Chemistry: 89.09 Da · C3H7NO2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL462547
Name	Urethane
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	5641
ChEBI	CHEBI:17967
Molecular formula	C3H7NO2
Molecular weight	89.09
InChIKey	JOYRKODLDBILNP-UHFFFAOYSA-N

SMILES: CCOC(=O)N

IUPAC name: ethyl carbamate

ChEBI definition: A carbamate ester obtained by the formal condensation of ethanol with carbamic acid. It has been found in alcoholic beverages.

Pharmacological roles (ChEBI): mutagen.

Other ChEBI roles (chemical / environmental): fungal metabolite.

Also known as: Carbamic acid, ethyl ester, Leucethane, NSC-746, O-ethylurethane, Pracarbamine, Uretano, Urethan, Urethane, SID26748777, URETHANE, SID144204951

Patent coverage: 924,501 distinct patent families (2,296,874 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Polyunsaturated fatty acid lipoxygenase ALOX15.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02018822	Not specified	COMPLETED	Evaluate the Effectiveness of an Experimental Urethane Dimethacrylate Resin Based Dental Composite Material

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).